Drug General Information
Drug ID	D0T5AW
Former ID	DIB004852
Drug Name	Desoxypeganine
Synonyms	Alcoholism therapy, HF Arzneimittelforschung; Desoxypeganine, HF Arzneimittelforschung
Drug Type	Small molecular drug
Indication	Alcohol use disorders [ICD9: 303; ICD10:F10.2]		Phase 1	[529540]
Company	HF Arzneimittelforschung GmbH & Co KG
Structure		Download 2D MOL 3D MOL
Formula	C11H12N2
Canonical SMILES	N1=C2N(Cc3c1cccc3)CCC2
CAS Number	CAS 495-59-0
PubChem Compound ID	442894
Target and Pathway
Target(s)	Acetylcholinesterase	Target Info	Modulator	[529540]
	Amine oxidase [flavin-containing] A	Target Info	Modulator	[529540]
BioCyc Pathway	Superpathway of tryptophan utilization
	Dopamine degradation
	Putrescine degradation III
	Noradrenaline and adrenaline degradation
	Serotonin degradation
	Superpathway of melatonin degradation
	Melatonin degradation II
KEGG Pathway	Glycerophospholipid metabolism
	Cholinergic synapsehsa00260:Glycine, serine and threonine metabolism
	Arginine and proline metabolism
	Histidine metabolism
	Tyrosine metabolism
	Phenylalanine metabolism
	Tryptophan metabolism
	Drug metabolism - cytochrome P450
	Metabolic pathways
	Serotonergic synapse
	Dopaminergic synapse
	Cocaine addiction
	Amphetamine addiction
	Alcoholism
NetPath Pathway	IL4 Signaling Pathway
PANTHER Pathway	Muscarinic acetylcholine receptor 1 and 3 signaling pathway
	Muscarinic acetylcholine receptor 2 and 4 signaling pathway
	Nicotinic acetylcholine receptor signaling pathwayP00001:Adrenaline and noradrenaline biosynthesis
	5-Hydroxytryptamine degredation
	Dopamine receptor mediated signaling pathway
Pathway Interaction Database	ATF-2 transcription factor network
PathWhiz Pathway	Phospholipid BiosynthesisPW000043:Histidine Metabolism
	Tyrosine Metabolism
	Glycine and Serine Metabolism
Reactome	Norepinephrine Neurotransmitter Release Cycle
WikiPathways	Monoamine Transport
	Biogenic Amine Synthesis
	Acetylcholine Synthesis
	Integrated Pancreatic Cancer PathwayWP706:SIDS Susceptibility Pathways
	Oxidative Stress
	Dopamine metabolism
	Phase 1 - Functionalization of compounds
	Neurotransmitter Release Cycle
	Neurotransmitter Clearance In The Synaptic Cleft
	Serotonin Transporter Activity
References
Ref 529540	Phase I clinical trial with desoxypeganine, a new cholinesterase and selective MAO-A inhibitor: tolerance and pharmacokinetics study of escalating single oral doses. Methods Find Exp Clin Pharmacol. 2008 Mar;30(2):141-7.
Ref 529540	Phase I clinical trial with desoxypeganine, a new cholinesterase and selective MAO-A inhibitor: tolerance and pharmacokinetics study of escalating single oral doses. Methods Find Exp Clin Pharmacol. 2008 Mar;30(2):141-7.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.